These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 21241384)

  • 21. State-of-the-art: Immunosuppression and biologic therapy.
    Sandborn WJ
    Dig Dis; 2010; 28(3):536-42. PubMed ID: 20926883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors].
    Steenholdt C; Ainsworth M; Thomsen OØ; Brynskov J; Bendtzen K
    Ugeskr Laeger; 2010 Jan; 172(1):44-7. PubMed ID: 20056095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Inflammatory bowel diseases].
    Felley C; Guyot J; Hess J; Mottet C; Delarive J; Michetti P
    Rev Med Suisse; 2005 Jan; 1(3):218-20, 223-7. PubMed ID: 15770816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum sickness, encephalitis and other complications of anti-cytokine therapy.
    Vermeire S; Van Assche G; Rutgeerts P
    Best Pract Res Clin Gastroenterol; 2009; 23(1):101-12. PubMed ID: 19258190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing response and loss of response to biological therapies in IBD.
    Yanai H; Hanauer SB
    Am J Gastroenterol; 2011 Apr; 106(4):685-98. PubMed ID: 21427713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.
    Lichtenstein GR; Diamond RH; Wagner CL; Fasanmade AA; Olson AD; Marano CW; Johanns J; Lang Y; Sandborn WJ
    Aliment Pharmacol Ther; 2009 Aug; 30(3):210-26. PubMed ID: 19392858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis?
    Danese S; Angelucci E
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S217-27. PubMed ID: 20117345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker.
    Danese S
    Dig Liver Dis; 2008 Jul; 40 Suppl 2():S225-8. PubMed ID: 18598993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease.
    Pearce CB; Lawrance IC
    J Gastroenterol Hepatol; 2007 Oct; 22(10):1671-7. PubMed ID: 17845695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maximizing the effect of biologics in inflammatory bowel disease.
    Souto Rodriguez R; Swoger JM; Barreiro-De Acosta M; Regueiro M
    Minerva Gastroenterol Dietol; 2012 Jun; 58(2):101-22. PubMed ID: 22643594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management consensus of inflammatory bowel disease for the Asia-Pacific region.
    Ouyang Q; Tandon R; Goh KL; Pan GZ; Fock KM; Fiocchi C; Lam SK; Xiao SD
    J Gastroenterol Hepatol; 2006 Dec; 21(12):1772-82. PubMed ID: 17074013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P; Van Assche G; Vermeire S
    Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G-->A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease.
    Sýkora J; Subrt I; Dìdek P; Siala K; Schwarz J; Machalová V; Varvarovská J; Pazdiora P; Pozler O; Stozický F
    J Pediatr Gastroenterol Nutr; 2006 May; 42(5):479-87. PubMed ID: 16707968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic problems and advances in inflammatory bowel disease.
    Odze R
    Mod Pathol; 2003 Apr; 16(4):347-58. PubMed ID: 12692200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine.
    Korelitz BI; Mirsky FJ; Fleisher MR; Warman JI; Wisch N; Gleim GW
    Am J Gastroenterol; 1999 Nov; 94(11):3248-53. PubMed ID: 10566724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease.
    Klotz U; Schwab M
    Adv Drug Deliv Rev; 2005 Jan; 57(2):267-79. PubMed ID: 15555742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
    Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
    Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug advances in inflammatory bowel disease.
    Speight RA; Mansfield JC
    Clin Med (Lond); 2013 Aug; 13(4):378-82. PubMed ID: 23908509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Will novel oral formulations change the management of inflammatory bowel disease?
    Nielsen OH; Seidelin JB; Ainsworth M; Coskun M
    Expert Opin Investig Drugs; 2016 Jun; 25(6):709-18. PubMed ID: 26967267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized Treatment.
    Dreesen E; Gils A; Vermeire S
    Curr Drug Targets; 2018; 19(7):757-776. PubMed ID: 26953243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.